Exhibiting at DIA/FDA Oligonucleotide-Based Therapeutics Conference 2026

Ajinomoto Bio-Pharma Services will exhibit at the DIA/FDA Oligonucleotide-Based Therapeutics Conference 2026, bringing together industry, regulatory authorities, and academia to discuss the latest advances in oligonucleotide therapeutics.

We will introduce our oligonucleotide manufacturing capabilities, including solid-phase synthesis, AJIPHASE®, and enzymatic ligation technologies.

We look forward to meeting you at our booth and discussing how we can support your development and manufacturing programs.